Neurolutions, Inc. and Kandu Health Announce Strategic Partnership to Accelerate Access to Breakthrough Brain Computer Interface (BCI) and Remote Support for Stroke Rehabilitation

– SANTA CRUZ and CAMPBELL, Calif.
November 8, 2023

Companies’ Post-Stroke Solutions Aim to Significantly Improve Recovery Journey for Patients and Their Families

Neurolutions Inc ., the leader in the use of non-invasive brain computer interface (BCI) technology for post-stroke therapy, and Kandu Health™, a tech enabled health care services company that is changing the course of stroke recovery and post-acute care, today announced a strategic partnership aimed to raise the standard of care for post-stroke recovery. Through this partnership, Kandu Health’s expert clinicians will support Neurolutions by providing clinical consultation and assessments of stroke survivors to determine patients who may benefit from Neurolution’s IpsiHand System.

Kandu Health provides remote, multidisciplinary support to stroke survivors and care partners after hospital discharge through a team of clinically licensed navigators and an easy-to-use app.The IpsiHand System is a breakthrough therapeutic device and the only FDA-cleared, commercially available solution that enables non-invasive, at-home rehabilitation for stroke survivors affected by chronic motor deficits. The alliance between Neurolutions and Kandu Health offers stroke survivors streamlined, expert clinical assessment for the IpsiHand System, reducing the barriers to accessing this life-changing technology.

Establishing Feasibility of a Post-Acute Stroke Navigation Platform

The award-winning ANVC 2023 poster by Lauren Sheehan, Sr. Director Clinical Services for Kandu Health, “Complex Needs & Dynamic Solutions – Metrics That Yield Outcomes in a Post-Acute Stroke Navigation Program,” evaluated how post-stroke impairments, Social Determinants of Health, and the presence of a care partner impact survivor engagement and outcomes in a remote post-acute stroke navigation program.

Jennifer Patterson, NP, Director of Neuroscience Operations at CHI Memorial Neuroscience Institute, who led the ANVC poster evaluation, said, “Stroke trials have traditionally categorized any patient who is able to live independently at 90 days (mRS 0-2) as having a ‘good outcome.’ What we see in the Kandu data is that 57% of patients achieving mRS 0-1 and 77% of those achieving mRS 2-3 engaged in 10 or more post-acute Navigator touchpoints over 12 weeks, demonstrating the significant need and opportunity for these services. Kandu’s ability to engage and support patients across a broad spectrum is encouraging.”

“We are excited to see the strong signal from this recent evidence that this work is important, our services are accessible to the communities they serve, and the outcomes we are generating are meaningful,” said Kirsten Carroll, CEO of Kandu Health. “We look forward to continued partnership with our stakeholders to generate additional clinical evidence that demonstrates our value and informs policy and standard of care for stroke survivors.”